These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors.
    Author: Ioannou M, Demertzis N, Iakovidou I, Kottakis S.
    Journal: Anticancer Res; 2007; 27(2):1143-7. PubMed ID: 17465254.
    Abstract:
    BACKGROUND: Extra-abdominal desmoid tumors are rare neoplasms with variable biological behavior. The mainstay of treatment is surgery. Complementary treatment with tyrosine-kinase receptor inhibitor drugs, particularly imatinib mesylate, has been reported in the literature. The purpose of this study was to determine the possible presence of tyrosine-kinase receptors in extra-abdominal desmoid tumors as a marker for imatinib mesylate therapy. PATIENTS AND METHODS: From 1999 to 2004, immunohistochemical methods were carried-out in 14 patients with histologically confirmed extra-abdominal desmoid tumors to determine c-KIT positivity (existence of tyrosine-kinase receptors and PDGFRA and PDGFRB). RESULTS: All desmoid tumors were c-KIT negative, which demonstrates absence of tyrosine-kinase receptors. CONCLUSION: The histological c-KIT markup is an easy and reliable method that can detect whether a desmoid tumor is sensitive to additional treatment with a tyrosine-kinase receptor inhibitor. Molecular biological analysis for the identification of KIT and PDGFR mutation should be performed before imatinib mesylate is included in any treatment protocol.
    [Abstract] [Full Text] [Related] [New Search]